Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.
Continued monitoring of absolute lymphocyte count (ALC) during treatment and follow-up can predict OS, results showed.
“The peripheral blood ALC is a readily available biomarker that can offer prognostication over time,” Grace M. Ferri, MD, internal medicine resident physician at Boston Medical Center, and colleagues wrote. “Based on our results, ALC measured every 6 months during the